Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes - PubMed (original) (raw)
. 2003 Feb 21;278(8):5828-36.
doi: 10.1074/jbc.M208132200. Epub 2002 Dec 16.
Affiliations
- PMID: 12486128
- DOI: 10.1074/jbc.M208132200
Free article
Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes
Cinzia Dello Russo et al. J Biol Chem. 2003.
Free article
Abstract
Activation of peroxisome proliferator-activated receptors (PPARs) can regulate brain physiology and provide protection in models of neurological disease; however, neither their exact targets nor mechanisms of action in brain are known. In many cells, PPAR gamma agonists increase glucose uptake and metabolism. Because astrocytes store glucose and provide lactate to neurons on demand, we tested effects of PPAR gamma agonists on astroglial glucose metabolism. Incubation of cortical astrocytes with the PPAR gamma thiazolidinedione (TZD) agonist pioglitazone (Pio) significantly increased glucose consumption in a time- and dose-dependent manner, with maximal increase of 36% observed after 4 h in 30 microm Pio. Pio increased 2-deoxy-glucose uptake because of increased flux through the type 1 glucose transporter. However, at this time point Pio did not increase type 1 glucose transporter expression, nor were its effects blocked by transcriptional or translational inhibitors. Pio also increased astrocyte lactate production as soon as 3 h after incubation. These effects were replicated by other TZDs; however, the order of efficacy (troglitazone > pioglitazone > rosiglitazone) suggests that effects were not mediated via PPAR gamma activation. TZDs increased astrocyte cAMP levels, and their glucose modifying effects were reduced by protein kinase A inhibitors. TZDs inhibited state III respiration in isolated brain mitochondria, whereas in astrocytes they caused mitochondrial membrane hyperpolarization. Pio protected astrocytes against hypoglycemia-induced cell death. Finally, glucose uptake was modified in brain sections prepared from Pio-fed rats. These results demonstrate that TZDs modify astrocyte metabolism and mitochondrial function, which could be beneficial in neurological conditions where glucose availability is reduced.
Similar articles
- Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.
Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhäusl W, Fürnsinn C. Brunmair B, et al. Diabetes. 2001 Oct;50(10):2309-15. doi: 10.2337/diabetes.50.10.2309. Diabetes. 2001. PMID: 11574413 - Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K, Kook H, Ueda M, Nakao K. Fukunaga Y, et al. Atherosclerosis. 2001 Sep;158(1):113-9. doi: 10.1016/s0021-9150(01)00430-0. Atherosclerosis. 2001. PMID: 11500181 - Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.
Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB. Wang YL, et al. J Biol Chem. 2002 Aug 30;277(35):31781-8. doi: 10.1074/jbc.M204279200. Epub 2002 Jun 24. J Biol Chem. 2002. PMID: 12082115 - [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Sugiyama Y, Murase K, Ikeda H. Sugiyama Y, et al. Nihon Rinsho. 2000 Feb;58(2):370-5. Nihon Rinsho. 2000. PMID: 10707560 Review. Japanese. - Metabolic and additional vascular effects of thiazolidinediones.
Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Martens FM, et al. Drugs. 2002;62(10):1463-80. doi: 10.2165/00003495-200262100-00004. Drugs. 2002. PMID: 12093315 Review.
Cited by
- Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.
Artwohl M, Fürnsinn C, Waldhäusl W, Hölzenbein T, Rainer G, Freudenthaler A, Roden M, Baumgartner-Parzer SM. Artwohl M, et al. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24. Diabetologia. 2005. PMID: 15729575 - Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.
Pizcueta P, Vergara C, Emanuele M, Vilalta A, Rodríguez-Pascau L, Martinell M. Pizcueta P, et al. Int J Mol Sci. 2023 Feb 6;24(4):3201. doi: 10.3390/ijms24043201. Int J Mol Sci. 2023. PMID: 36834611 Free PMC article. Review. - How does pioglitazone prevent progression of impaired glucose tolerance to diabetes?
Genuth SM. Genuth SM. Diabetes. 2013 Nov;62(11):3663-5. doi: 10.2337/db13-1175. Diabetes. 2013. PMID: 24158994 Free PMC article. No abstract available. - A rational pharmacologic approach toward a biologically meaningful subtype of autism spectrum disorder.
Neumeyer AM, Thom RP, McDougle CJ. Neumeyer AM, et al. J Pediatr (Rio J). 2021 Jan-Feb;97(1):1-3. doi: 10.1016/j.jped.2020.05.001. Epub 2020 May 27. J Pediatr (Rio J). 2021. PMID: 32473111 Free PMC article. No abstract available. - Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities.
McIntyre RS, Vagic D, Swartz SA, Soczynska JK, Woldeyohannes HO, Voruganti LP, Konarski JZ. McIntyre RS, et al. CNS Drugs. 2008;22(6):443-53. doi: 10.2165/00023210-200822060-00001. CNS Drugs. 2008. PMID: 18484789 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources